Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

Iwata, Takehiro; Sadahira, Takuya; Maruyama, Yuki; Sekito, Takanori; Yoshinaga, Kasumi; Watari, Shogo; Nagao, Kentaro; Kawada, Tatsushi; Tominaga, Yusuke; Nishimura, Shingo; Takamoto, Atsushi; Sako, Tomoko; Edamura, Kohei; Kobayashi, Yasuyuki; Araki, Motoo; Ishii, Ayano; Watanabe, Masami; Watanabe, Toyohiko; Nasu, Yasutomo; Wada, Koichiro

ID	62820
JaLCDOI	10.18926/AMO/62820
FullText URL	75_6_763.pdf 1.84 MB
Author	Iwata, Takehiro Department of Urology, Okayama University Hospital Kaken ID Sadahira, Takuya Department of Urology, Okayama University Hospital Maruyama, Yuki Department of Urology, Okayama University Hospital Sekito, Takanori Department of Urology, Okayama University Hospital Yoshinaga, Kasumi Department of Urology, Okayama University Hospital Watari, Shogo Department of Urology, Okayama University Hospital Nagao, Kentaro Department of Urology, Okayama University Hospital Kawada, Tatsushi Department of Urology, Okayama University Hospital Tominaga, Yusuke Department of Urology, Okayama University Hospital Nishimura, Shingo Department of Urology, Okayama University Hospital Takamoto, Atsushi Department of Urology, Okayama University Hospital Sako, Tomoko Department of Urology, Okayama University Hospital Edamura, Kohei Department of Urology, Okayama University Hospital Kobayashi, Yasuyuki Department of Urology, Okayama University Hospital ORCID Kaken ID Araki, Motoo Department of Urology, Okayama University Hospital ORCID Kaken ID publons researchmap Ishii, Ayano Department of Urology, Okayama University Hospital Kaken ID publons researchmap Watanabe, Masami Department of Urology, Okayama University Hospital Kaken ID publons researchmap Watanabe, Toyohiko Department of Urology, Okayama University Hospital ORCID Kaken ID publons researchmap Nasu, Yasutomo Department of Urology, Okayama University Hospital Kaken ID publons researchmap Wada, Koichiro Department of Urology, Okayama University Hospital ORCID researchmap
Abstract	The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
Keywords	genitourinary tract infections fluoroquinolone resistance extended-spectrum beta-lactamase
Amo Type	Clinical Study Protocol
Publication Title	Acta Medica Okayama
Published Date	2021-12
Volume	volume75
Issue	issue6
Publisher	Okayama University Medical School
Start Page	763
End Page	766
ISSN	0386-300X
NCID	AA00508441
Content Type	Journal Article
language	English
Copyright Holders	Copyright Ⓒ 2021 by Okayama University Medical School
File Version	publisher
Refereed	True
PubMed ID	34955548
Web of Science KeyUT	000735319800006
NAID	120007180272